COMPASS Trial Reveals Positive Regimen for Patients with Peripheral Artery Disease

COMPASS Trial Reveals Positive Regimen for Patients with Peripheral Artery Disease

The COMPASS trial revealed that patients with stable atherosclerotic vascular disease tremendously benefit from 2.5 mg Xarelto twice daily, plus 100 mg aspirin once daily. This regimen was found to have not only reduced the risk of a second cardiovascular event (e.g.,...

Pin It on Pinterest